Display options
Cite
Phillips S, Mistry S, Riva A, et al. Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients. Front Immunol. 2017;8:621doi: 10.3389/fimmu.2017.00621.
Phillips, S., Mistry, S., Riva, A., Cooksley, H., Hadzhiolova-Lebeau, T., Plavova, S., Katzarov, K., Simonova, M., Zeuzem, S., Woffendin, C., Chen, P. J., Peng, C. Y., Chang, T. T., Lueth, S., De Knegt, R., Choi, M. S., Wedemeyer, H., Dao, M., Kim, C. W., Chu, H. C., Wind-Rotolo, M., Williams, R., Cooney, E., & Chokshi, S. (2017). Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients. Frontiers in immunology, 8621. https://doi.org/10.3389/fimmu.2017.00621
Phillips, Sandra, et al. "Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients." Frontiers in immunology vol. 8 (2017): 621. doi: https://doi.org/10.3389/fimmu.2017.00621
Phillips S, Mistry S, Riva A, Cooksley H, Hadzhiolova-Lebeau T, Plavova S, Katzarov K, Simonova M, Zeuzem S, Woffendin C, Chen PJ, Peng CY, Chang TT, Lueth S, De Knegt R, Choi MS, Wedemeyer H, Dao M, Kim CW, Chu HC, Wind-Rotolo M, Williams R, Cooney E, Chokshi S. Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients. Front Immunol. 2017 May 29;8:621. doi: 10.3389/fimmu.2017.00621. eCollection 2017. PMID: 28611778; PMCID: PMC5446997.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2017 May 29;8:621. doi: 10.3389/fimmu.2017.00621. eCollection 2017.

Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients.

Frontiers in immunology

Sandra Phillips, Sameer Mistry, Antonio Riva, Helen Cooksley, Tanya Hadzhiolova-Lebeau, Slava Plavova, Krum Katzarov, Marieta Simonova, Stephan Zeuzem, Clive Woffendin, Pei-Jer Chen, Cheng-Yuan Peng, Ting-Tsung Chang, Stefan Lueth, Robert De Knegt, Moon-Seok Choi, Heiner Wedemeyer, Michael Dao, Chang-Wook Kim, Heng-Chen Chu, Megan Wind-Rotolo, Roger Williams, Elizabeth Cooney, Shilpa Chokshi

Affiliations

  1. Institute of Hepatology, Foundation for Liver Research, London, United Kingdom.
  2. Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
  3. Clinic of Gastroenterology and Hepatology, Military Medical Academy, Sofia, Bulgaria.
  4. Johann Wolfgang, Goethe University Medical Center, Frankfurt, Germany.
  5. Oregon Clinical and Translational Research Institute, Portland, OR, United States.
  6. National Taiwan University Hospital, Taipei, Taiwan.
  7. China Medical University Hospital, Taichung, Taiwan.
  8. National Chen Kung University Hospital, Tainan, Taiwan.
  9. University of Hamburg, Hamburg, Germany.
  10. Erasmus University, Rotterdam, Netherlands.
  11. Sungkyunkwan University, Seoul, South Korea.
  12. Hannover Medical School, Hannover, Germany.
  13. Precision Diagnostic Laboratory, Santa Ana, CA, United States.
  14. The Catholic University of Korea, Seoul, South Korea.
  15. Tri-Service General Hospital, Taipei, Taiwan.
  16. Research and Development, Bristol-Myers Squibb, Wallingford, CT, United States.

PMID: 28611778 PMCID: PMC5446997 DOI: 10.3389/fimmu.2017.00621

Abstract

IFN-lambda (IFNλ) is a member of the type III IFN family and is reported to possess anti-pathogen, anti-cancer, and immunomodulatory properties; however, there are limited data regarding its impact on host immune responses

CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT01204762.

Keywords: direct antiviral; hepatitis B; immunity; in vivo; peg-interferon lambda

References

  1. J Hepatol. 2011 Feb;54(2):209-18 - PubMed
  2. Hum Immunol. 2014 Sep;75(9):996-1000 - PubMed
  3. J Exp Med. 2007 Mar 19;204(3):667-80 - PubMed
  4. Gut. 2012 May;61 Suppl 1:i18-24 - PubMed
  5. Cell Death Differ. 2008 Feb;15(2):226-33 - PubMed
  6. J Hepatol. 2016 May;64(5):1011-9 - PubMed
  7. Blood. 2011 Feb 24;117(8):2385-95 - PubMed
  8. Hepatology. 2014 Aug;60(2):487-96 - PubMed
  9. PLoS Pathog. 2012;8(3):e1002594 - PubMed
  10. J Leukoc Biol. 2009 Dec;86(6):1359-63 - PubMed
  11. J Clin Virol. 2013 Dec;58(4):713-7 - PubMed
  12. Antimicrob Agents Chemother. 2008 Jan;52(1):312-20 - PubMed
  13. Hepatology. 2000 Nov;32(5):1117-24 - PubMed
  14. PLoS Pathog. 2010 Dec 16;6(12):e1001227 - PubMed
  15. Gastroenterology. 2009 Sep;137(3):1151-60, 1160.e1-7 - PubMed
  16. J Immunol. 2008 Jun 15;180(12):7785-91 - PubMed
  17. Cell Mol Gastroenterol Hepatol. 2015 Nov;1(6):578-588 - PubMed
  18. Genes Immun. 2009 Dec;10(8):702-14 - PubMed
  19. J Infect Dis. 2015 Oct 1;212(7):1042-51 - PubMed
  20. Gastroenterology. 2015 Mar;148(3):590-602.e10 - PubMed
  21. J Viral Hepat. 2013 Apr;20(4):e11-9 - PubMed
  22. J Exp Med. 2000 Apr 17;191(8):1269-80 - PubMed
  23. Antiviral Res. 2015 Sep;121:47-58 - PubMed
  24. Gastroenterology. 2010 Feb;138(2):682-93, 693.e1-4 - PubMed
  25. Virol J. 2014 Mar 17;11:51 - PubMed
  26. Cytokine Growth Factor Rev. 2001 Jun-Sep;12 (2-3):143-56 - PubMed
  27. Sci Rep. 2015 Nov 20;5:16459 - PubMed
  28. Virology. 2010 Jun 5;401(2):197-206 - PubMed
  29. Curr Opin Virol. 2011 Dec;1(6):476-86 - PubMed
  30. Hepatology. 2006 Oct;44(4):896-906 - PubMed
  31. J Clin Invest. 1996 Sep 1;98(5):1185-94 - PubMed
  32. J Virol. 2011 Jun;85(12):5929-39 - PubMed
  33. Antivir Ther. 2007;12(5):705-18 - PubMed
  34. PLoS Pathog. 2014 Jan;10 (1):e1003845 - PubMed
  35. PLoS Pathog. 2008 Mar 14;4(3):e1000017 - PubMed
  36. Eur J Immunol. 2015 Jan;45(1):250-9 - PubMed
  37. Hepatol Int. 2015 Jan;9(1):9-16 - PubMed
  38. Immunology. 2011 Apr;132(4):466-74 - PubMed
  39. J Hepatol. 2014 Jan;60(1):54-61 - PubMed
  40. Sci Rep. 2016 Aug 22;6:31349 - PubMed
  41. Swiss Med Wkly. 2012 May 09;142:w13586 - PubMed
  42. EMBO Mol Med. 2011 Jun;3(6):348-61 - PubMed
  43. J Virol. 2006 May;80(9):4501-9 - PubMed
  44. Hepatology. 1997 Jun;25(6):1497-501 - PubMed
  45. J Hepatol. 2013 Feb;58(2):225-33 - PubMed
  46. Blood. 2009 Jun 4;113(23):5829-38 - PubMed
  47. J Immunol. 2010 Jan 1;184(1):287-95 - PubMed
  48. J Hepatol. 2012 Jul;57(1):167-85 - PubMed
  49. PLoS Pathog. 2011 Dec;7(12):e1002407 - PubMed
  50. Hepatology. 2008 Sep;48(3):759-69 - PubMed
  51. N Engl J Med. 2006 Mar 9;354(10):1001-10 - PubMed
  52. J Gastroenterol. 2013 Jan;48(1):13-21 - PubMed
  53. Hepatology. 2009 Jan;49(1):72-9 - PubMed
  54. J Clin Invest. 2011 Mar;121(3):1088-101 - PubMed
  55. Cell Death Dis. 2015 Mar 19;6:e1694 - PubMed
  56. Methods. 1996 Apr;9(2):370-8 - PubMed
  57. Hepatology. 2010 Oct;52(4):1232-41 - PubMed
  58. J Immunol. 2006 Jun 15;176(12):7686-94 - PubMed
  59. J Immunol. 2007 Apr 15;178(8):5086-98 - PubMed
  60. J Virol. 2004 Jun;78(11):5707-19 - PubMed
  61. Nat Rev Immunol. 2002 Feb;2(2):85-95 - PubMed
  62. Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5736-41 - PubMed
  63. J Clin Virol. 2012 May;54(1):93-5 - PubMed
  64. Viral Immunol. 2014 Jun;27(5):235-44 - PubMed
  65. Br J Pharmacol. 2013 Mar;168(5):1048-58 - PubMed
  66. Bone Marrow Transplant. 1997 Apr;19(8):795-9 - PubMed
  67. Gastroenterology. 2006 Dec;131(6):1887-98 - PubMed
  68. Clin Liver Dis. 2016 Nov;20(4):645-665 - PubMed
  69. J Interferon Cytokine Res. 2016 Dec;36(12 ):671-680 - PubMed
  70. Ann Gastroenterol. 2014;27(2):105-112 - PubMed
  71. J Infect Dis. 1998 Dec;178(6):1585-91 - PubMed
  72. J Infect Dis. 2009 Mar 15;199(6):819-28 - PubMed
  73. Gastroenterology. 2012 Oct;143(4):963-73.e9 - PubMed
  74. Virol J. 2012 Jan 10;9:10 - PubMed
  75. Hepatology. 2009 Apr;49(4):1141-50 - PubMed
  76. BMC Infect Dis. 2008 Sep 22;8:123 - PubMed
  77. Genes Immun. 2007 Apr;8(3):254-61 - PubMed
  78. J Hepatol. 2012 Jun;56(6):1239-46 - PubMed
  79. J Virol. 2007 Apr;81(8):4215-25 - PubMed

Publication Types